2. INTRODUCTION
Bleeding into the alveolar spaces characterizes the
syndrome of DAH and is due to disruption of the
alveolar-capillary basement membrane. This is
caused by injury or inflammation of the
arterioles, venules, or alveolar septal (alveolar
wall or interstitial) capillaries. Hemoptysis is the
usual presenting symptom; however it is not
always present, even when hemorrhage is severe
3.
4.
5.
6.
7. CLINICAL PRESENTATION
Symptoms :Cough, hemoptysis, fever, and dyspnea
are common initial symptoms. Some patients,
however, present with ARDS requiringMV
Physical examination: The pulmonary examination
is usually nonspecific, unless there are physical
signs of an underlying systemic vasculitis or CT
vascular disorder
8. INVESTIGATIONS
Radiological:
PFTs: increased DLCO
BAL :sequential lavage are progressively more
hemorrhagic with hemosiderin-ladenMQ.
Biopsy from the affected tissue
9.
10.
11.
12. TREATMENT
=TTT CAUSE
Glucocorticoids : are the mainstay of therapy for
the DAH syndrome associated with systemic
vasculitis, connective tissue disease, Goodpasture's
syndrome, and isolated pulmonary capillaritis.
Additional immunosuppressive
agents (cyclophosphamide or azathioprine)
Plasma exchange : in Goodpasture's syndrom
